Trial reportRadiation oncology (London, England)2025
Early prediction of parotid glands secretory function based on ADC variations during radiotherapy for nasopharyngeal carcinoma: a phase II prospective study.
Trial report in Radiation oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Longitudinal bilateral parotid delta-radiomic kinetics and variance signatures for prediction of late xerostomia following radiotherapy.BMC medical imaging · 2026Article
- Advanced magnetic resonance imaging techniques for structural and functional assessment of salivary glands.Radiology and oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
objectivesThis study aimed to quantify dynamic changes in the Apparent Diffusion Coefficient (ADC) values of the parotid glands during radiotherapy and explore their correlation with early-stage gland dysfunction.
methodsNasopharyngeal carcinoma patients receiving definitive chemoradiotherapy were prospectively enrolled. Magnetic Resonance Diffusion-Weighted Imaging (MR-DWI) was performed at pre-radiotherapy (pre-RT), the 5th, 15th fractions, and end of radiotherapy. ADC values and volumes for ipsilateral (IP) and contralateral parotid glands (CP) were recorded. Salivary function was assessed using scintigraphy (SGS) and the Radiation Therapy Oncology Group (RTOG) xerostomia criteria.
resultsA total of 80 eligible patients were analyzed. From pre-radiotherapy(pre-RT) to the end of radiotherapy, Pearson correlation analysis showed that changes in ADC values were positively correlated with the delivered dose (p < 0.01) and reduction in parotid volume (p < 0.01).From pre-RT to the 5th fraction, mean ADC values((ΔADC5) increased significantly by 17.7% (IP) and 16.3% (CP) (p < 0.01), with minimal volume changes(ΔrV5) (p = 0.060, p = 0.068). Spearman analysis revealed a positive association between the change in ΔADC5 and the incidence of xerostomia 6 months after radiotherapy (p < 0.01). Multivariable analysis identified ΔADC5 rather than ΔrV5 as an independent predictor of secretory dysfunction (IP: Odds Ratio (OR) = 1.010, p = 0.015 by SGS; OR = 1.026, p = 0.000 by RTOG; CP: OR = 1.017, p = 0.004 by SGS; OR = 1.015, p = 0.002 by RTOG).
conclusionThis study analyze the dynamic changes in parotid gland ADC values, volume, and secretion function throughout radiotherapy. Changes in ΔADC5 can predict radiation-induced parotid gland injury before significant volume changes occur, thereby enabling early intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.